Risperidone Patent Expiration
Risperidone is used for treating various conditions such as depression, anxiety, and obsessive-compulsive disorder. It was first introduced by Janssen Pharmaceuticals Inc
Risperidone Patents
Given below is the list of patents protecting Risperidone, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Uzedy | US12128132 | Drug delivery formulations | Sep 11, 2040 | Teva |
Uzedy | US9023897 | Biodegradable drug delivery compositions | Apr 05, 2033 | Teva |
Rykindo | US10098882 | Risperidone sustained release microsphere composition | Apr 10, 2032 | Shandong Luye |
Rykindo | US10406161 | Risperidone sustained release microsphere composition | Apr 10, 2032 | Shandong Luye |
Rykindo | US11110094 | Risperidone sustained release microsphere composition | Apr 10, 2032 | Shandong Luye |
Rykindo | US9446135 | Risperidone sustained release microsphere composition | Apr 10, 2032 | Shandong Luye |
Rykindo | US9532991 | Risperidone sustained release microsphere composition | Apr 10, 2032 | Shandong Luye |
Risvan | US10058504 | Methods for the preparation of injectable depot compositions | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US10085936 | Antipsychotic injectable depot composition | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US10182982 | Antipsychotic injectable depot composition | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US10195138 | Methods for the preparation of injectable depot compositions | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US10335366 | Risperidone or paliperidone implant formulation | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US10463607 | Antipsychotic Injectable Depot Composition | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US10881605 | Methods for the preparation of injectable depot compositions | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US11007139 | Risperidone or paliperidone implant formulation | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US11173110 | Risperidone or paliperidone implant formulation | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US11241377 | Antipsychotic injectable depot composition | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US11752092 | Methods for the preparation of injectable depot compositions | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US11752093 | Antipsychotic injectable depot composition | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US11752094 | Antipsychotic injectable depot composition | May 31, 2031 | Labs Farms Rovi Sa |
Risvan | US11759416 | Antipsychotic injectable depot composition | May 31, 2031 | Labs Farms Rovi Sa |
Perseris Kit | US10010612 | Sustained delivery formulations of risperidone compounds | Feb 13, 2028 | Indivior |
Perseris Kit | US10376590 | Sustained delivery formulations of risperidone compound | Feb 13, 2028 | Indivior |
Perseris Kit | US11013809 | Sustained delivery formulations of risperidone compound | Feb 13, 2028 | Indivior |
Perseris Kit | US11712475 | Sustained delivery formulations of risperidone compound | Feb 13, 2028 | Indivior |
Perseris Kit | US9180197 | Sustained delivery formulations of risperidone compounds | Feb 13, 2028 | Indivior |
Perseris Kit | US9186413 | Sustained delivery formulations of risperidone compounds | Feb 13, 2028 | Indivior |
Uzedy | US8221778 | Drug-containing implants and methods of use thereof | Nov 12, 2027 | Teva |
Uzedy | US8741327 | Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant | Nov 12, 2027 | Teva |
Perseris Kit | US11110093 | Sustained release small molecule drug formulation | Nov 05, 2026 | Indivior |
Perseris Kit | US10058554 | Sustained release small molecule drug formulation | Sep 26, 2026 | Indivior |
Perseris Kit | US9597402 | Sustained release small molecule drug formulation | Sep 26, 2026 | Indivior |
Perseris Kit | US10406160 | Sustained release small molecule drug formulation | Jun 26, 2026 | Indivior |
Uzedy | US10736965 | Risperidone biodegradable implant |
Jan 12, 2025
(Expired) | Teva |
Uzedy | US8802127 | Risperidone-containing PLA:PGA implants and methods of use thereof |
Jan 12, 2025
(Expired) | Teva |
Uzedy | US9439905 | Risperidone-containing implants and methods of use thereof |
Jan 12, 2025
(Expired) | Teva |
Uzedy | US9717799 | Drug-containing implants and methods of use thereof |
Jan 12, 2025
(Expired) | Teva |
Uzedy | US9895447 | Drug-containing PLA implants and methods of use thereof |
Jan 12, 2025
(Expired) | Teva |
Uzedy | US9925268 | Drug-containing implants and methods of use thereof |
Jan 12, 2025
(Expired) | Teva |
Risperdal Consta |
US6667061 (Pediatric) | Preparation of injectable suspensions having improved injectability |
Nov 25, 2020
(Expired) | Janssen Pharms |
Risperdal Consta | US6667061 | Preparation of injectable suspensions having improved injectability |
May 25, 2020
(Expired) | Janssen Pharms |
Risperdal Consta |
US6194006 (Pediatric) | Preparation of microparticles having a selected release profile |
Jun 30, 2019
(Expired) | Janssen Pharms |
Risperdal Consta |
US6379703 (Pediatric) | Preparation of microparticles having a selected release profile |
Jun 30, 2019
(Expired) | Janssen Pharms |
Risperdal Consta |
US6596316 (Pediatric) | Preparation of microparticles having a selected release profile |
Jun 30, 2019
(Expired) | Janssen Pharms |
Risperdal Consta | US6194006 | Preparation of microparticles having a selected release profile |
Dec 30, 2018
(Expired) | Janssen Pharms |
Risperdal Consta | US6379703 | Preparation of microparticles having a selected release profile |
Dec 30, 2018
(Expired) | Janssen Pharms |
Risperdal Consta | US6596316 | Preparation of microparticles having a selected release profile |
Dec 30, 2018
(Expired) | Janssen Pharms |
Risperdal |
US6224905 (Pediatric) | Biconvex rapidly disintegrating dosage forms |
Dec 10, 2017
(Expired) | Janssen Pharms |
Risperdal Consta |
US5792477 (Pediatric) | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
Nov 02, 2017
(Expired) | Janssen Pharms |
Risperdal Consta |
US5916598 (Pediatric) | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
Nov 02, 2017
(Expired) | Janssen Pharms |
Risperdal Consta |
US6403114 (Pediatric) | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
Nov 02, 2017
(Expired) | Janssen Pharms |
Risperdal | US6224905 | Biconvex rapidly disintegrating dosage forms |
Jun 10, 2017
(Expired) | Janssen Pharms |
Risperdal Consta | US5792477 | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
May 02, 2017
(Expired) | Janssen Pharms |
Risperdal Consta | US5916598 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
May 02, 2017
(Expired) | Janssen Pharms |
Risperdal Consta | US6403114 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
May 02, 2017
(Expired) | Janssen Pharms |
Risperdal Consta |
US5688801 (Pediatric) | Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May 18, 2015
(Expired) | Janssen Pharms |
Risperdal |
US5648093 (Pediatric) | Pharmaceutical and other dosage forms |
Jan 15, 2015
(Expired) | Janssen Pharms |
Risperdal |
US5453425 (Pediatric) | Risperidone oral formulation |
Jan 11, 2015
(Expired) | Janssen Pharms |
Risperdal |
USRE39181 (Pediatric) | Aqueous risperidone formulations |
Jan 11, 2015
(Expired) | Janssen Pharms |
Risperdal Consta | US5688801 | Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov 18, 2014
(Expired) | Janssen Pharms |
Risperdal | US5648093 | Pharmaceutical and other dosage forms |
Jul 15, 2014
(Expired) | Janssen Pharms |
Risperdal | US5453425 | Risperidone oral formulation |
Jul 11, 2014
(Expired) | Janssen Pharms |
Risperdal | USRE39181 | Aqueous risperidone formulations |
Jul 11, 2014
(Expired) | Janssen Pharms |
Risperdal Consta |
US5965168 (Pediatric) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May 19, 2014
(Expired) | Janssen Pharms |
Risperdal Consta |
US6110921 (Pediatric) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May 19, 2014
(Expired) | Janssen Pharms |
Risperdal Consta |
US6368632 (Pediatric) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May 19, 2014
(Expired) | Janssen Pharms |
Risperdal Consta |
US7547452 (Pediatric) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May 19, 2014
(Expired) | Janssen Pharms |
Risperdal Consta | US5965168 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov 19, 2013
(Expired) | Janssen Pharms |
Risperdal Consta | US6110921 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov 19, 2013
(Expired) | Janssen Pharms |
Risperdal Consta | US6368632 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov 19, 2013
(Expired) | Janssen Pharms |
Risperdal Consta | US7547452 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov 19, 2013
(Expired) | Janssen Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Risperidone's patents.
Latest Legal Activities on Risperidone's Patents
Given below is the list recent legal activities going on the following patents of Risperidone.
Activity | Date | Patent Number |
---|---|---|
![]() | ||
Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jul, 2024 | US9532991 |
Surcharge for Late Payment, Large Entity | 17 Apr, 2024 | US10736965 |
Payment of Maintenance Fee, 4th Year, Large Entity | 17 Apr, 2024 | US10736965 |
Maintenance Fee Reminder Mailed Critical
| 01 Apr, 2024 | US10736965 |
Payment of Maintenance Fee, 8th Year, Large Entity | 19 Mar, 2024 | US9446135 |
Payment of Maintenance Fee, 8th Year, Large Entity | 28 Feb, 2024 | US9439905 |
Payment of Maintenance Fee, 12th Yr, Small Entity | 03 Jan, 2024 | US8221778 |
Payment of Maintenance Fee, 4th Year, Large Entity | 10 Mar, 2023 | US10406161 |
Payment of Maintenance Fee, 8th Year, Large Entity | 02 Nov, 2022 | US9023897 |
Payment of Maintenance Fee, 4th Year, Large Entity | 28 Mar, 2022 | US10098882 |
Risperidone's Family Patents
